Top Story

Next generation sequencing increases actionable mutation detection in malignant melanoma

April 26, 2015

NEW YORK — The use of next-generation sequencing in multi-gene targeted panel testing identified a considerable number of actionable mutations among patients with malignant melanoma, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.

Multi-gene panel testing through next-generation sequencing has become a valuable strategy to identify actionable mutations and yield prognostic information in patients with molecular melanoma. Due to the increasing number of approved therapies that target specific pathways, next-generation sequencing may help identify ideal treatments, according to study background.

Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma Meeting News CoverageVideo

Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

April 25, 2015
NEW YORK — Igor Puzanov, MD, MSCI, FACP, director of clinical melanoma research at Vanderbilt University, presents data from patients with melanoma who were…
Meeting News Coverage

Durable response to T-VEC, GM-CSF linked to longer OS

April 25, 2015
NEW YORK — Patients with unresected stage IIIB, stage IIIc or stage IV melanoma who achieved durable response to either talimogene laherparepvec or…
Meeting News Coverage

Algorithm predicts HCC in patients with cirrhosis

April 25, 2015
VIENNA — A new algorithm accurately predicted hepatocellular carcinoma among a cohort of patients with cirrhosis, according to a study presented at the 2015…
Cover StoryPublication Exclusive

Expansion of ‘Right to Try’ legislation raises ethical, safety concerns

HemOnc Today, April 25, 2015
Early access to experimental drugs has historically been reserved for patients enrolled on clinical trials.In 2009, the FDA revamped its 1980’s expanded access program…
More News Headlines »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
VIDEO: Registry data reconfirm the role of high-dose IL-2 in melanoma

VIDEO: Registry data reconfirm the role of high-dose IL-2 in melanoma

April 24, 2015
NEW YORK — Howard L. Kaufman, MD, FACP, associate director for clinical science at the Rutgers Cancer Institute…
More »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
morganatic-roan